文献速递肝病

年龄与性别对原发性胆汁性胆管炎患者熊去氧胆酸应答及无移植生存的影响

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-01-04

基于全球PBC研究队列4355例成人患者的纵向回顾性研究显示,男性起始治疗年龄更大且胆红素更高、血小板更低;年龄大于45岁者基于GLOBE评分的生化应答几率更高,大于65岁者应答几率最高(OR 5.48),而年龄≤35岁者肝移植或死亡风险显著升高(HR 14.59);多变量分析中性别与应答及无移植生存无独立关联。

要点

  • 年龄大于45岁起始UDCA治疗者生化应答几率高于年轻患者,大于65岁者应答几率最高(OR 5.48)。
  • 年龄≤35岁者肝移植或死亡风险显著高于一般人群(HR 14.59),大于65岁者风险降低(HR 1.39)。
  • 多变量分析中性别与UDCA应答及无移植生存无独立关联。

核心结论

  • 在4355例成人全球PBC研究队列的纵向分析中,患者年龄而非性别与UDCA治疗应答及无移植生存相关。
  • 起始治疗时年龄较轻与治疗失败、肝移植和死亡风险增加相关。

研究设计与样本

  • 纵向回顾性研究,纳入全球PBC研究队列中来自欧洲和北美17个中心的4355例成人患者。
  • 患者于1961年至2014年间诊断为原发性胆汁性胆管炎。
  • 采用逻辑回归和Cox回归分别评估性别和年龄对基于GLOBE评分的UDCA应答及无移植生存的影响。

主要发现

  • 男性起始治疗年龄大于女性(58.3±12.1岁 vs 54.3±11.6岁;P<.0001),且胆红素水平更高、循环血小板计数更低(P<.0001)。
  • 年龄≤45岁患者血清转氨酶水平高于年龄>45岁患者。
  • 起始治疗时年龄>45岁患者基于GLOBE评分的UDCA生化应答几率高于年轻患者;年龄>65岁患者应答几率最高(与年龄≤45岁患者相比,OR 5.48;95%CI 3.92-7.67;P<.0001)。
  • 与按年龄、性别和出生年份匹配的一般人群相比,肝移植或死亡风险随年龄增长显著降低:年龄≤35岁患者HR 14.59(95%CI 9.66-22.02)vs 年龄>65岁患者HR 1.39(95%CI 1.23-1.57)(P<.0001)。
  • 多变量分析中,性别与应答或无移植生存无独立关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary biliary cholangitis (PBC) predominantly affects middle-aged women; there are few data on disease phenotypes and outcomes of PBC in men and younger patients. We investigated whether differences in sex and/or age at the start of ursodeoxycholic acid (UDCA) treatment are associated with response to therapy, based on biochemical markers, or differences in transplant-free survival. METHODS: We performed a longitudinal retrospective study of 4355 adults in the Global PBC Study cohort, collected from 17 centers across Europe and North America. Patients received a diagnosis of PBC from 1961 through 2014. We evaluated the effects of sex and age on response to UDCA treatment (based on GLOBE score) and transplant-free survival using logistic regression and Cox regression analyses, respectively. RESULTS: Male patients were older at the start of treatment (58.3±12.1 years vs 54.3±11.6 years for women; P<.0001) and had higher levels of bilirubin and lower circulating platelet counts (P<.0001). Younger patients (45 years or younger) had increased serum levels of transaminases than older patients (older than 45 years). Patients older than 45 years at time of treatment initiation had increased odds of a biochemical response to UDCA therapy, based on GLOBE score, compared to younger patients. The greatest odds of response to UDCA were observed in patients older than 65 years (odds ratio compared to younger patients 45 years or younger, 5.48; 95% CI, 3.92-7.67; P<.0001). Risk of liver transplant or death (compared to a general population matched for age, sex, and birth year) decreased significantly with advancing age: hazard ratio for patients 35 years or younger, 14.59 (95% CI, 9.66-22.02) vs hazard ratio for patients older than 65 years, 1.39 (95% CI, 1.23-1.57) (P<.0001). On multivariable analysis, sex was not independently associated with response or transplant-free survival. CONCLUSION: In longitudinal analysis of 4355 adults in the Global PBC Study, we associated patient age, but not sex, with response to UDCA treatment and transplant-free survival. Younger age at time of treatment initiation is associated with increased risk of treatment failure, liver transplant, and death.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cheung AC, Lammers WJ, Murillo Perez CF, et al. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2019. PMID: 30616022. doi:10.1016/j.cgh.2018.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。